
-
MediWound NasdaqGM:MDWD MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
Location: 42 Hayarkon Street, Yavne, 8122745, Israel | Website: https://www.mediwound.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
198.6M
Cash
38.27M
Avg Qtr Burn
-3.282M
Short % of Float
12.50%
Insider Ownership
17.97%
Institutional Own.
44.29%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
NexoBrid Details Eschar removal, Thermal burns | Approved Quarterly sales | |
EscharEx Details Venous Leg Ulcers | Phase 3 Data readout | |
MW005 Details Basal cell carcinoma, Cancer, Non-melanoma skin cancer, Skin cancer | Phase 1/2 Update |